Strategic Partnerships 3B Pharmaceuticals has a history of licensing and collaboration with major players in oncology (Clovis Oncology, Debiopharm, RefleXion). This suggests potential opportunities for new licensing, co-development, or supply agreements surrounding radiopharmaceuticals and targeted radiotherapy.

Radiopharmaceutical Focus The company specializes in targeted radiopharmaceutical therapeutics and diagnostics for oncology, indicating opportunities to position services or collaborations around radioligand development, imaging probes, and CAIX-targeting programs similar to Debio 0228.

Strategic Expansion Recent licensing activity and asset sales with RefleXion imply a pivot toward scalable partnerships and expanded patient reach via radiotherapy platforms, presenting doors for BD approaches centered on access to radiotherapy-enabled populations.

Access to Expertise With a CMO transition and a background of successful leadership moves, there is a potential to engage in advisory or consulting engagements, as well as joint development discussions leveraging experienced leadership to accelerate program milestones.

Financial and Market Signals Revenue is in the low to mid single digits with a lean team (51-200 employees), suggesting a need for cost-effective collaborations, CRO/CMO outsourcing, or milestone-driven partnerships to balance financial risk while advancing radiopharmaceutical programs.